Dihydroartemisinin-piperaquine

Access

-

Approved

Eurartesim®

Alfasigma

3-day cure, artemisinin-based combination therapies (TPP-1)

Therapeutic indication	Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5 kg
Dosing	Once daily for 3 days
Efficacy	28-day PCR-corrected ACPR* 94.7-99.9% 42-day PCR-corrected ACPR* 91.5%–99.3% *ACPR=adequate clinical and parasitological response
Key features	Comparatively long post-treatment protection 2-year shelf life
Challenges	European Medicines Agency (EMA) cardiac monitoring guidance Confirmed piperaquine resistance in Greater Mekong Sub-region
Status	First stringent regulatory approval by EMA in 2011 Approvals in 24 countries Distributed 8.9 million doses to date
Next milestone	Submit application for marketing authorisation for dispersible paediatric formulation to EMA Publish results of cardiac safety and pharmacokinetics study in pregnancy in Tanzania
Project Director	Adam Aspinall